From: Treatment pathways and associated costs of metastatic colorectal cancer in Greece
 | Administration | Strength/pack | Hospital prices—5%, unit cost (€) | Cost per mg (€) |
---|---|---|---|---|
Irinotecana | IV | 20 mg/ml × 15 ml | 147.31 | 0.47 |
Folinic acida | IV | 10 mg/ml × 20 ml | 11.2 | 0.03 |
Fluorouracila | IV | 50 mg/ml × 100 ml | 14.14 | 0.0028 |
Cetuximab | IV | 5 mg/ml × 20 ml | 132.26 | 1.32 |
Panitumumab | IV | 20 mg/ml × 20 ml | 1100.28 | 2.75 |
Bevacizumab | IV | 25 mg/ml × 4ml | 204.52 | 2.05 |
Aflibercept | Intravitreal | 25 mg/ml × 4 ml | 250.27 | 2.50 |
Oxaliplatin | IV | 5 mg/ml × 10 ml | 19.82 | 0.40 |
Capecitabine | Oral | 150 mg/tab × 60 tabs | 10.66 | 0.002 |
Nivolumab | IV | 10 mg/ml × 24 ml | 2106.87 | 8.78 |
Pembrolizumab | IV | 25 mg/ml × 4 ml | 2229.89 | 22.30 |
Encorafenib | Oral | 75 mg/ml × 42 caps | 1046.92 | 0.33 |
Tas102 (Trifluridine-tiporacil) | Oral | (15 + 6.14) mg/tab × 20 tabs | 445.92 | 1.05 |
Regorafenib | Oral | 40 mg/tab × 84 tabs | 1884.71 | 0.56 |
Mitomycin-C | IV | 2 mg/vial × 10 vials | 15.91 | 0.84 |